Clinical Trial

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-09
Trial Details
NCT Number NCT07444268
Lead Sponsor Sumitomo Pharma America, Inc.
Conditions Advanced Hematologic Malignancies
Enrollment 8 participants
Start Date 2026-03-26
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-08